AI news that drew views this week (Jan. 18-22)

The NIH, FDA and Bill and Melinda Gates Foundation are working with a San Francisco startup whose calling card is an AI-enabled engine that renders patient data unidentifiable by reproducing it in synthetic versions.

Last Tuesday the FDA posted an action plan telling how it will evaluate AI for medical applications going forward. Three days later the agency officially proposed letting numerous products through without review. 

One turnoff is remote food monitoring. Another is real-time feedback—whether from a live healthcare professional or an AI algorithm.

The FDA’s new Digital Health Center of Excellence has released a document describing how it will henceforth oversee and evaluate software that incorporates AI and machine learning for medical applications.

After perusing info on AI startups as compiled by Crunchbase, Forbes senior contributor Louis Columbus has named one “to watch” in 2021 that serves exclusively healthcare.

The idea is to head off serious gathering threats without getting thrown off the scent by strains unlikely to proliferate.

AI melanoma detectors that equaled or bettered dermatologists in clinical trials have stumbled on the way to the real world of patient care. 

Under a new proposal, 91 products would no longer require U.S. Food & Drug Administration regulatory review, including a number of radiology-driven platforms.

Researchers have long-believed software that performed well on this deep learning model would automatically translate to improvements during medical imaging assignments.

Hyperfine said its new deep-learning software can aid in measuring brain structure and pathology in images obtained by its Swoop product.